This note discusses some recent projections of future costs to the Commonwealth Pharmaceutical Benefits Scheme. Author, Maurice Rickard, observes that care should be taken in basing future projections on past PBS growth trends and in comparing PBS growth with growth in other areas of Commonwealth health expenditure.